Floatz logo

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR, CSF-1R, CSF-1-R, MACROPHAGE COLONYSTIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)), HUMANIZED MONOCLONAL ANTIBODY

Recurrent Ovarian Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
81/ 100

Competitive context

245 Active assets in the Recurrent Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR, CSF-1R, CSF-1-R, MACROPHAGE COLONYSTIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)), HUMANIZED MONOCLONAL ANTIBODY is also rated in:

fallopian tube clear cell adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
fallopian tube adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
fallopian tube endometrioid adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →